Immunomedics Company Profile (NASDAQ:IMMU)

About Immunomedics (NASDAQ:IMMU)

Immunomedics logoImmunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:IMMU
  • CUSIP: 45290710
  • Web: www.immunomedics.com
Capitalization:
  • Market Cap: $1.28 billion
  • Outstanding Shares: 111,279,000
Average Prices:
  • 50 Day Moving Avg: $10.09
  • 200 Day Moving Avg: $7.94
  • 52 Week Range: $2.02 - $12.96
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -44.12
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $3.09 million
  • Price / Sales: 413.06
  • Book Value: ($0.53) per share
  • Price / Book: -21.64
Profitability:
  • EBIDTA: ($71,330,000.00)
  • Net Margins: -4,956.52%
  • Return on Assets: -109.37%
Debt:
  • Debt-to-Equity Ratio: -1.65%
  • Current Ratio: 1.29%
  • Quick Ratio: 1.28%
Misc:
  • Average Volume: 2.57 million shs.
  • Beta: 1.65
  • Short Ratio: 19.33
 

Frequently Asked Questions for Immunomedics (NASDAQ:IMMU)

What is Immunomedics' stock symbol?

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

How were Immunomedics' earnings last quarter?

Immunomedics, Inc. (NASDAQ:IMMU) released its quarterly earnings data on Wednesday, August, 16th. The company reported ($0.25) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.12) by $0.13. The firm had revenue of $0.64 million for the quarter, compared to analysts' expectations of $0.75 million. Immunomedics's revenue for the quarter was down 31.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.17) EPS. View Immunomedics' Earnings History.

Where is Immunomedics' stock going? Where will Immunomedics' stock price be in 2017?

3 analysts have issued 12-month price objectives for Immunomedics' shares. Their predictions range from $14.00 to $15.00. On average, they expect Immunomedics' share price to reach $14.50 in the next twelve months. View Analyst Ratings for Immunomedics.

Are investors shorting Immunomedics?

Immunomedics saw a increase in short interest in August. As of August 31st, there was short interest totalling 34,287,202 shares, an increase of 0.6% from the August 15th total of 34,074,923 shares. Based on an average daily volume of 4,662,516 shares, the days-to-cover ratio is currently 7.4 days. Approximately 34.4% of the shares of the company are short sold.

Who are some of Immunomedics' key competitors?

Who are Immunomedics' key executives?

Immunomedics' management team includes the folowing people:

  • Jason M. Aryeh, Chairman of the Board
  • Cynthia L. Sullivan, President, Chief Executive Officer, Director
  • Michael R. Garone, Chief Financial Officer, Vice President - Finance
  • David M. Goldenberg, Chief Scientific Officer, Chief Patent Officer, Director
  • Geoffrey F. Cox Ph.D., Independent Director
  • Robert Forrester, Independent Director
  • Brian A. Markison, Lead Independent Director
  • Bob Oliver, Independent Director

Who owns Immunomedics stock?

Immunomedics' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (5.02%), State Street Corp (4.37%), Vanguard Group Inc. (4.13%), Farallon Capital Management LLC (3.83%), Palo Alto Investors LLC (2.73%) and First Light Asset Management LLC (1.86%). Company insiders that own Immunomedics stock include Cynthia L Goldenberg, David M Goldenberg, Don C Stark and Mary E Paetzold. View Institutional Ownership Trends for Immunomedics.

Who sold Immunomedics stock? Who is selling Immunomedics stock?

Immunomedics' stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Chicago Equity Partners LLC, Virtu KCG Holdings LLC, First Light Asset Management LLC, Atlantic Trust Group LLC, UBS Asset Management Americas Inc., IFP Advisors Inc and Swiss National Bank. Company insiders that have sold Immunomedics stock in the last year include Cynthia L Goldenberg and David M Goldenberg. View Insider Buying and Selling for Immunomedics.

Who bought Immunomedics stock? Who is buying Immunomedics stock?

Immunomedics' stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Palo Alto Investors LLC, State Street Corp, Lord Abbett & CO. LLC, Jennison Associates LLC, Goldman Sachs Group Inc., DAFNA Capital Management LLC and EAM Investors LLC. View Insider Buying and Selling for Immunomedics.

How do I buy Immunomedics stock?

Shares of Immunomedics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Immunomedics' stock price today?

One share of Immunomedics stock can currently be purchased for approximately $11.47.


MarketBeat Community Rating for Immunomedics (NASDAQ IMMU)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  145 (Vote Outperform)
Underperform Votes:  115 (Vote Underperform)
Total Votes:  260
MarketBeat's community ratings are surveys of what our community members think about Immunomedics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Immunomedics (NASDAQ:IMMU) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.50 (26.42% upside)

Analysts' Ratings History for Immunomedics (NASDAQ:IMMU)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/19/2017Jefferies Group LLCBoost Price TargetBuy$11.00 -> $14.00HighView Rating Details
7/24/2017Cowen and CompanyReiterated RatingOutperform$15.00LowView Rating Details
5/5/2017Wells Fargo & CoUpgradeMarket Perform -> OutperformHighView Rating Details
(Data available from 9/25/2015 forward)

Earnings

Earnings History for Immunomedics (NASDAQ:IMMU)
Earnings by Quarter for Immunomedics (NASDAQ:IMMU)
Earnings History by Quarter for Immunomedics (NASDAQ IMMU)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/16/2017Q4 2017($0.12)($0.25)$0.75 million$0.64 millionViewN/AView Earnings Details
2/9/2017Q2 2017($0.13)($0.16)$0.70 million$0.38 millionViewListenView Earnings Details
11/2/2016Q117($0.14)($0.17)$0.70 million$0.74 millionViewN/AView Earnings Details
8/17/2016Q416($0.11)($0.17)$0.90 million$0.93 millionViewListenView Earnings Details
5/4/2016Q3($0.13)($0.15)$0.70 million$0.90 millionViewN/AView Earnings Details
2/3/2016Q216($0.14)($0.15)$1.40 million$0.67 millionViewN/AView Earnings Details
11/4/2015Q116($0.14)($0.16)$1.23 million$0.73 millionViewN/AView Earnings Details
8/19/2015Q415($0.13)($0.13)$1.13 million$2.40 millionViewListenView Earnings Details
5/6/2015Q3 2015($0.13)($0.13)$1.07 million$1.18 millionViewN/AView Earnings Details
2/4/2015Q215($0.13)($0.12)$1.73 million$1.00 millionViewN/AView Earnings Details
11/5/2014Q1 2015($0.12)($0.13)$1.18 million$1.07 millionViewN/AView Earnings Details
8/25/2014Q414($0.13)($0.13)$1.20 million$1.20 millionViewN/AView Earnings Details
5/7/2014Q3 2014($0.12)$0.02$1.13 million$1.15 millionViewN/AView Earnings Details
2/10/2014Q214($0.10)($0.10)$1.20 million$1.20 millionViewN/AView Earnings Details
8/22/2013Q4 2013($0.12)($0.09)$0.81 million$1.40 millionViewN/AView Earnings Details
5/8/2013Q3 2013($0.10)$0.11$0.97 million$1.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Immunomedics (NASDAQ:IMMU)
2017 EPS Consensus Estimate: ($0.53)
2018 EPS Consensus Estimate: ($0.56)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.12)($0.12)($0.12)
Q2 20171($0.15)($0.15)($0.15)
Q3 20171($0.15)($0.15)($0.15)
Q4 20171($0.11)($0.11)($0.11)
Q1 20181($0.11)($0.11)($0.11)
Q2 20181($0.12)($0.12)($0.12)
Q3 20181($0.14)($0.14)($0.14)
Q4 20181($0.19)($0.19)($0.19)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Immunomedics (NASDAQ:IMMU)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Immunomedics (NASDAQ:IMMU)
Insider Ownership Percentage: 6.60%
Institutional Ownership Percentage: 77.99%
Insider Trades by Quarter for Immunomedics (NASDAQ:IMMU)
Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)
Insider Trades by Quarter for Immunomedics (NASDAQ:IMMU)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/1/2017David M. GoldenbergInsiderSell20,000$12.64$252,800.00View SEC Filing  
8/28/2017Cynthia L. GoldenbergDirectorSell40,000$10.72$428,800.00View SEC Filing  
8/23/2017Cynthia L. GoldenbergDirectorSell40,000$9.24$369,600.00View SEC Filing  
8/24/2016Don C StarkDirectorSell9,900$2.97$29,403.00View SEC Filing  
8/23/2016Mary E PaetzoldDirectorSell15,000$2.98$44,700.00View SEC Filing  
6/13/2016Cynthia L GoldenbergCEOSell371,990$3.03$1,127,129.70View SEC Filing  
6/8/2016Cynthia L GoldenbergCEOSell41,441$3.62$150,016.42View SEC Filing  
6/8/2016David M GoldenbergChairmanSell353,010$3.88$1,369,678.80View SEC Filing  
6/7/2016Cynthia L GoldenbergCEOSell4,600$4.01$18,446.00View SEC Filing  
6/7/2016David M GoldenbergChairmanSell12,300$3.98$48,954.00View SEC Filing  
6/6/2016Cynthia L GoldenbergCEOSell63,959$4.09$261,592.31View SEC Filing  
6/6/2016David M GoldenbergChairmanSell110,322$4.09$451,216.98View SEC Filing  
6/15/2015David M GoldenbergChairmanSell210,991$4.08$860,843.28View SEC Filing  
6/12/2015Brian A MarkisonDirectorSell5,564$4.22$23,480.08View SEC Filing  
6/12/2015David M GoldenbergChairmanSell359,653$4.32$1,553,700.96View SEC Filing  
6/9/2015Mary E PaetzoldDirectorSell4,677$4.60$21,514.20View SEC Filing  
6/5/2015Don C StarkDirectorSell5,732$4.14$23,730.48View SEC Filing  
12/11/2014Mary E PaetzoldDirectorSell10,000$4.71$47,100.00View SEC Filing  
12/9/2014Don C StarkDirectorSell5,500$4.51$24,805.00View SEC Filing  
9/13/2013Don StarkDirectorSell10,000$6.08$60,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Immunomedics (NASDAQ:IMMU)
Latest Headlines for Immunomedics (NASDAQ:IMMU)
Source:
DateHeadline
americanbankingnews.com logoImmunomedics, Inc. (IMMU) Given New $14.00 Price Target at Jefferies Group LLC
www.americanbankingnews.com - September 24 at 1:00 PM
streetinsider.com logoForm 8-K IMMUNOMEDICS INC For: Sep 19 - StreetInsider.com
www.streetinsider.com - September 22 at 7:02 PM
americanbankingnews.com logoJefferies Group Research Analysts Reduce Earnings Estimates for Immunomedics, Inc. (IMMU)
www.americanbankingnews.com - September 21 at 11:20 AM
finance.yahoo.com logoImmunomedics Announces Agreements to Exchange Approximately $80.0 Million of Its 4.75% Convertible Senior Notes Due 2020 for Common Stock
finance.yahoo.com - September 16 at 1:40 AM
seekingalpha.com logoImmunomedics (IMMU) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 14 at 6:28 AM
americanbankingnews.com logoImmunomedics, Inc. (IMMU) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - September 13 at 2:53 PM
reuters.com logoBRIEF-Immunomedics presents interim phase 2 results with sacituzumab govitecan (i
www.reuters.com - September 12 at 1:39 AM
finance.yahoo.com logoImmunomedics Presents Interim Phase 2 Results With Sacituzumab Govitecan (IMMU-132) in Patients With Pretreated Metastatic Urothelial Cancer
finance.yahoo.com - September 12 at 1:39 AM
streetinsider.com logoImmunomedics (IMMU) Reports Interim Phase 2 Results With Sacituzumab Govitecan (IMMU-132) - StreetInsider.com
www.streetinsider.com - September 11 at 8:36 PM
nasdaq.com logoAre Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock? - Nasdaq
www.nasdaq.com - September 11 at 8:36 PM
americanbankingnews.com logoImmunomedics, Inc. (IMMU) Insider David M. Goldenberg Sells 20,000 Shares
www.americanbankingnews.com - September 5 at 10:26 PM
nasdaq.com logoIMMU Crosses Above Average Analyst Target - Nasdaq
www.nasdaq.com - September 1 at 8:13 PM
finance.yahoo.com logoImmunomedics to Participate in Upcoming Investor Conferences
finance.yahoo.com - August 31 at 6:10 AM
investopedia.com logoImmunomedics Stock Breaks Out, Consolidation Likely
www.investopedia.com - August 30 at 2:08 AM
americanbankingnews.com logoImmunomedics, Inc. (IMMU) Director Sells $428,800.00 in Stock
www.americanbankingnews.com - August 28 at 10:22 PM
americanbankingnews.com logoImmunomedics, Inc. (IMMU) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - August 28 at 8:44 PM
finance.yahoo.com logoETFs with exposure to Immunomedics, Inc. : August 28, 2017
finance.yahoo.com - August 28 at 7:28 PM
fool.com logoHere's Why Immunomedics Rose as Much as 14.2% Today
www.fool.com - August 28 at 4:58 PM
feeds.benzinga.com logoMid-Day Market Update: Crude Oil Down 2.5%; MaxPoint Interactive Shares Spike Higher
feeds.benzinga.com - August 28 at 12:52 PM
finance.yahoo.com logoImmunomedics, Inc. :IMMU-US: Earnings Analysis: Q4, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 25 at 7:05 AM
feeds.benzinga.com logoMid-Afternoon Market Update: Crude Oil Down Over 2%; Abercrombie & Fitch Shares Surge Following Strong Q2 Results
feeds.benzinga.com - August 24 at 3:10 PM
streetinsider.com logoForm 4 IMMUNOMEDICS INC For: Aug 21 Filed by: GOLDENBERG DAVID M
www.streetinsider.com - August 24 at 7:58 AM
finance.yahoo.com logoImmunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : August 22, 2017
finance.yahoo.com - August 24 at 7:58 AM
americanbankingnews.com logoImmunomedics, Inc. (IMMU) Director Cynthia L. Goldenberg Sells 40,000 Shares
www.americanbankingnews.com - August 24 at 4:20 AM
reuters.com logoBRIEF-Immunomedics announces publication of cancer drug data - Reuters
www.reuters.com - August 22 at 12:05 AM
globenewswire.com logoResults Appeared in Advanced Online Publication of the American Society of Clinical Oncology Journal, Journal of Clinical Oncology
globenewswire.com - August 21 at 8:51 AM
finance.yahoo.com logoImmunomedics Announces Publication of Phase 2 Results With Labetuzumab Govitecan (IMMU-130) That Demonstrate Promising Efficacy as a Single Agent in Patients With Metastatic Colorectal Cancer
finance.yahoo.com - August 21 at 8:51 AM
americanbankingnews.com logoImmunomedics, Inc. Forecasted to Earn Q1 2018 Earnings of ($0.10) Per Share (IMMU)
www.americanbankingnews.com - August 21 at 6:22 AM
americanbankingnews.com logoImmunomedics, Inc. (IMMU) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - August 19 at 12:52 PM
americanbankingnews.com logoFY2022 EPS Estimates for Immunomedics, Inc. Cut by Analyst (IMMU)
www.americanbankingnews.com - August 18 at 2:28 PM
americanbankingnews.com logoImmunomedics, Inc. (IMMU) PT Set at $11.00 by Jefferies Group LLC
www.americanbankingnews.com - August 18 at 11:22 AM
americanbankingnews.com logoImmunomedics, Inc. (IMMU) Releases Earnings Results, Misses Expectations By $0.13 EPS
www.americanbankingnews.com - August 17 at 9:20 AM
reuters.com logoBRIEF-Immunomedics reports Q4 loss per share $0.48
www.reuters.com - August 17 at 5:54 AM
finance.yahoo.com logoEdited Transcript of IMMU earnings conference call or presentation 16-Aug-17 9:00pm GMT
finance.yahoo.com - August 17 at 5:54 AM
seekingalpha.com logoImmunomedics' (IMMU) Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 17 at 12:52 AM
finance.yahoo.com logoImmunomedics, Inc. – Value Analysis (NASDAQ:IMMU) : August 17, 2017
finance.yahoo.com - August 17 at 12:52 AM
nasdaq.com logoAfter-Hours Earnings Report for August 16, 2017 : CSCO, NTAP, LB, VIPS, CACI, BGG, SPTN, IMMU, GPRK, PBIO - Nasdaq
www.nasdaq.com - August 16 at 7:49 PM
globenewswire.com logoImmunomedics Announces Fiscal 2017 Results and Strategic Developments; Reiterates Guidance on BLA Submission ... - GlobeNewswire (press release)
globenewswire.com - August 16 at 7:49 PM
finance.yahoo.com logoImmunomedics Announces Fiscal 2017 Results and Strategic Developments; Reiterates Guidance on BLA Submission Timeline
finance.yahoo.com - August 16 at 7:49 PM
finance.yahoo.com logoImmunomedics reports 4Q loss
finance.yahoo.com - August 16 at 7:49 PM
americanbankingnews.com logoZacks Investment Research Lowers Immunomedics, Inc. (IMMU) to Hold
www.americanbankingnews.com - August 11 at 12:28 AM
finance.yahoo.com logoImmunomedics Announces Conference Call and Webcast for Fourth Quarter and Fiscal Year 2017 Results
finance.yahoo.com - August 7 at 7:15 PM
americanbankingnews.com logoImmunomedics, Inc. (IMMU) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - August 4 at 11:52 PM
reuters.com logoBRIEF-Immunomedics, Covance enter into master services agreement
www.reuters.com - August 4 at 8:07 PM
finance.yahoo.com logoImmunomedics, Inc. breached its 50 day moving average in a Bearish Manner : IMMU-US : August 3, 2017
finance.yahoo.com - August 3 at 7:57 PM
americanbankingnews.com logoImmunomedics, Inc. (IMMU) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - July 25 at 3:07 PM
americanbankingnews.com logoCowen and Company Reaffirms Outperform Rating for Immunomedics, Inc. (NASDAQ:IMMU)
www.americanbankingnews.com - July 24 at 4:10 PM
americanbankingnews.com logoImmunomedics, Inc. (IMMU) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - July 18 at 12:56 AM
americanbankingnews.com logoFY2019 Earnings Forecast for Immunomedics, Inc. (NASDAQ:IMMU) Issued By Jefferies Group
www.americanbankingnews.com - July 17 at 11:11 AM
americanbankingnews.com logoJefferies Group LLC Reaffirms "Buy" Rating for Immunomedics, Inc. (IMMU)
www.americanbankingnews.com - July 15 at 4:12 PM

Social

Chart

Immunomedics (IMMU) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by MarketBeat.com Staff